Vision Care for Eye Care Professionals
To Consumer Web
back
Vision Care
recommended searches
popular searches
ZEISS i.Scription Technology
ZEISS FOR EYE CARE PROFESSIONALS

ZEISS i.Scription Technology

Offer your patients improved vision, day and night.

i.Scription  Technology allows you to create a personal vision fingerprint through ZEISS  i.Profiler plus, to offer each patient a unique lens solution with improved vision day and night.

Get in touch
  • Better visual contrast
  • Better color vision
  • Better vision at night and in low light

Did you know?

  • 90%

    of patients want to recover their natural vision and are worried about vision health.1

  • 95%

    of wearers prefer ZEISS Individual  Single Vision Lenses  optimized  with  i.Scription® Technology versus ZEISS Individual  Single Vision Lenses without i.Scription.2

Is the way we understand refraction still relevant?

Why our approach to refraction is important.

Traditional refraction still serves as the basis for eyeglass lens prescriptions. This is the result of a two-part process:

  • Objective refraction: The refractive errors of the eye are first estimated objectively using retinoscopy or autorefraction followed by  

  • Subjective refraction: A prescription is subjectively refined by an eye doctor, allowing the patient to compare their vision through trial lenses, using either a refractor head or trial frame.  

Subjective refraction uses different eyeglass lens powers to correct refractive errors (such as myopia,  hyperopia  or astigmatism) in the eye, which are called low order  aberrations  (LOAs).  

However, due to variations in pupil size with varying light conditions, other types of aberrations  occur, affecting the quality of vision. These affect the final quality of vision experienced by the wearer. This is referred to as high order aberrations, HOAs (e.g. coma, trefoil, and spherical aberration).  

How does i.Scription Technology work?

i.Scription®    Technology by ZEISS is based on the ZEISS eye measuring system called the  i.Profiler®  plus, specifically designed to determine the exact “fingerprint” of the eyes and provide measurements unique to the patient’s eyes.  

A  ZEISS  i.Scription  prescription takes the effects of low and high order aberrations on retinal image quality  into account  by measuring up to 1,500 points on each eye.  This is done to provide improved vision corrections that deliver optimal visual performance  over a broader range of luminance levels, even under demanding viewing conditions like night driving.  

i.Scription® Technology analyses the circle of least confusion to provide the most accurate prescription possible.

More information
How does i.Scription Technology work?
How does i.Scription Technology work?

Let’s take a closer look.

Wavefront aberrations represent a convenient way to  characterize  complex optical errors produced by an optical system. At any point across the aperture of the optical system, such as the pupil, the wavefront error is the effective optical separation between the actual aberrated wavefront and the ideal reference wavefront.  

The overall shape of the wavefront aberration can be modelled and quantified mathematically and modelled using polynomials. Zernike polynomials are used to  characterize  the optical aberrations of the eye.  

What are low order aberrations (LOAs)?

What are low order aberrations (LOAs)?

LOAs are associated with the sphere and cylindrical power of the eye or optical lens; they include defocus and oblique- as well as with-the-rule/against-the-rule astigmatism. They have the greatest impact on the quality of vision and are traditionally corrected with prescription eyeglass lenses or contact lenses.

What are higher order aberrations (HOAs)?

What are higher order aberrations (HOAs)?

HOAs  characterize  the more subtle deviations of an aberrated wavefront from the ideal shape. They tend to have less impact than LOAs on the quality of vision. HOAs tend to have a greater impact on visual performance at lower luminance levels when the individual's pupil is larger than average, such as when driving at night.  

i.Scription® Technology combines low-order (LOAs) and higher-order aberrations (HOAs) to provide the most accurate prescription for better vision day and night by  analyzing  the image quality in the retina.

Why is i.Scription® Technology particularly beneficial in low light conditions?

Conventional manifest refraction is performed in  well-illuminated  rooms, leading to prescription values that work well in daylight situations. However, as the pupil dilates in low light conditions, the peripheral aberrations of the eye can lead to refractive shifts, resulting in a conventional prescription which is no longer valid.  

More information
Why is i.Scription Technology particularly beneficial in low light conditions?

Optimal Day and Night Vision

i.Scription®    Technology is able to combine the information about peripheral aberrations provided by  i.Profiler® plus with manifest refraction. The result is an  optimized,  personalized  prescription, delivering optimal day and night vision for the patient.

Eye care professionals and patients will experience the benefits

Benefits for eye care professionals include:

  • Provides  a bespoke vision solution for every patient.
  • Delivers  the best prescription for the patient, enhancing their vision and their overall viewing experience.
  • Fine-tunes the refraction to 1/100th of a diopter.
  • Reduces chair time through optimal refraction.
  • Provides a differentiating factor  from    competitors.
More information
Eye care professionals and patients will experience the benefits

Patient Benefits

No two people see the world in  exactly the same  way. Make sure you can provide every one of your patients with a personal vision solution that perfectly suits their needs.  

Patients will benefit from the best ZEISS technology in the following ways:  

  • Better  vision,  day  and  night  

  • Higher resolution, higher contrast and more vivid  colors  

  • Reduced  glare  effects  

Patients were convinced by the performance of lenses with i.Scription® Technology.

  • Subjects rated ZEISS lenses with i.Scription higher for distance vision, night vision, and color perception.3 

  • ZEISS lenses with i.Scription Technology also performed better on average than conventional eyeglass lenses in measures of mesopic visual acuity and contrast sensitivity.3 

  • Subjects with low- to moderate-prescription powers preferred ZEISS lenses with i.Scription Technology more often for distance vision, active vision, sharpness, changing focus, and overall vision.4 

  • Subjects preferred ZEISS lenses with i.Scription Technology more often for night vision, vividness of colors, and having less glare.4 

  • ZEISS lenses with i.Scription Technology also performed better than conventional eyeglass lenses in measures of low-contrast, mesopic visual acuity by approximately half a line of acuity.4 

  • Third-party Content Blocked

    The video player is blocked due to your cookie preferences. To change the settings and play the video, please click the button below and consent to use of "Functional" tracking technologies.

Contact Us

Become a ZEISS partner

Form is loading...

The information entered in the contact form will be used to answer your request by  Carl Zeiss Vision Canada by E-Mail or phone.  Click here  to read our statement on data protection.

Schedule an appointment

Form is loading...

The information entered in the contact form will be used to answer your request by  Carl Zeiss Vision Canada by E-Mail or phone. Click here to read our statement on data protection.

  • 1

    IMW-KÖLN study 2015, wearers of eyeglasses (n = 11,845).
  • 2

    Kevin Reeder, OD, Earl Sandler, OD, Joel Cook, OD, and Lynette Potgieter, B. Optom (RSA) – The Carmel Mountain Study (Orange County, California), double-blind test on preference between ZEISS i.Scription Lenses and comparable ZEISS free-form test lenses (n=37), 2016.
  • 3

    InSight Eyecare, Missouri. Double-mask clinical study (n=40).
  • 4

    Clinical Research Center of the School of Optometry at the University of California. Berkeley. Clinical study (n=30).